Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 4, 2003, Pages 382-385

  Jani, Ashesh B ^a   Basu, Anirban ^a   Abdalla, Ibrahim ^a   Connell, Phillip P ^a   Krauz, Lani ^a   Vijayakumar, Srinivasan ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Hormone therapy; Prostate cancer; Radiation oncology; Retrospective review

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AGED; BEAM THERAPY; BIOCHEMISTRY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; EARLY CANCER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RADIATION DOSE; REVIEW; SCORING SYSTEM; STATISTICAL ANALYSIS;

ADENOCARCINOMA; AGED; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; FLUTAMIDE; GOSERELIN; HUMANS; MALE; NEOADJUVANT THERAPY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0042062543     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200308000-00016     Document Type: Review

References (22)

1. Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol 1997;15:331-5.
2. Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000;163:1802-7.
3. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
4. Hanks GE. Conformal radiotherapy for prostate cancer. Ann Med 2000;32:57-63.
5. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-99.
6. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 2001;49:61-9.
7. Huggins C. Endocrine-induced regression of cancers. Science 1967;156:1050-4.
8. Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000;164:1465-72.
9. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997;49(suppl 3A):38-45.
10. Yang FE, Chen GTY, Ray P, et al. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 1995;33:1009-17.
11. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8.
12. Messing EM, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
13. Fellows GJ, Clark PB, Beynon LL, et al. Treatment of advanced localized prostatic cancer by orchiectomy, radiotherapy, or combined treatment. Br J Urol 1992;70:304-9.
14. Pilepich MV, Krall JM, al Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostate carcinoma: a randomized comparative trial of the RTOG. Urology 1995;45:616-23.
15. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
16. Laverdiere J, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247-52.
17. Hanks GE, Lu JD, Machtay M, et al. RTOG Protocol 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2000;48(suppl 3):112.
18. Garnick MB, Fair WR. First international conference on neoadjuvant hormonal therapy of prostate cancer: overview consensus statement. Urology 1997;49(suppl 3A):1-4.
19. D'Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000;284:1280-3.
20. Radiation Therapy Oncology Group. A phase III trial of the study of endocrine therapy used as a cytoreductive and cytostatic agent prior to radiation therapy in good prognosis locally confined adenocarcinoma of the prostate. (RTOG 94-08 protocol).
21. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
22. Stege R. Potential side-effects of endocrine treatment of long duration in prostate cancer. Prostate 2000;10(suppl):38-42.